09688.HK
Zai Lab Limited
HKSE · Healthcare · Biotechnology · CN
HKD 20.76
−1.42%Aug 9, 2026, 11:55 UTC
Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.
Source:Aug 6, 2026, 10:30 UTC
Zai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.
Aug 3, 2026, 11:00 UTC
The U.S. FDA granted Orphan Drug Designation to Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas.
Source:Jun 9, 2026, 00:34 UTC
China's NMPA approved Zai Lab's Biologics License Application for TIVDAK (tisotumab vedotin for injection) to treat recurrent or metastatic cervical cancer.
Source: